AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35764955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg AEO BID
Number of subjects: 119
Study 35764955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg AEO TID
Number of subjects: 119
Study 35764955 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg AEO BID (Long COVID)
Number of subjects: 119
Study 35764955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg AEO (Long COVID)
Number of subjects: 119
Study 35764955 — intervention group
Group type: COMPARATOR
Intervention: Historical placebo
Number of subjects: 119
Study 33417346 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neurostimulation device
Number of subjects: 52
Study 33417346 — intervention group
Group type: COMPARATOR
Intervention: Inactive (sham) device
Number of subjects: 52
Study 33026304 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with Aspergillus niger isolates An-1 and An-2 on surface-disinfected leaves of MLT.
Number of subjects: 100
Study 33026304 — intervention group
Group type: COMPARATOR
Intervention: Control group (unwounded leaves inoculated with An-1 and An-2).
Number of subjects: 100
Study 35156893 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-FMT
Number of subjects: 83
Study 35156893 — intervention group
Group type: COMPARATOR
Intervention: Placebo FMT
Number of subjects: 83
Study 32602555 — intervention group
Group type: COMPARATOR
Intervention: Historical placebo data
Number of subjects: 0
Study 32602555 — intervention group
Group type: COMPARATOR
Intervention: Current approaches to historical controls
Number of subjects: 0
Study 32602555 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed path forward
Number of subjects: 0
Study 35964170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) therapy (15 sessions)
Number of subjects: 60
Study 35964170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) (9 sessions)
Number of subjects: 60
Study 33517038 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Intensity Functional Exercise (HIFE) program targeting lower limb strength, balance and mobility exercise
Number of subjects: 186
Study 33517038 — intervention group
Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study 33517038 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Intensity Functional Exercise (HIFE) program
Number of subjects: 186
Study 33087406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid
Number of subjects: 100
Study 33087406 — intervention group
Group type: COMPARATOR
Intervention: Control (without cognitive aid)
Number of subjects: 100
Study 35818187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic IMRT in combination with chemotherapy (Taxol and Carboplatin)
Number of subjects: 114
Study 35818187 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT in combination with chemotherapy (Taxol and Carboplatin)
Number of subjects: 114
Study 32266567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentoxol mouthrinse 5 times/day
Number of subjects: 108
Study 32266567 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 108
Study 35218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (Tele-CBT)
Number of subjects: 81
Study 32690536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suvorexant (20 mg) once daily starting the night after extubation
Number of subjects: 120
Study 32690536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34247463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation follow-up program
Number of subjects: 33
Study 35202552 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust (DE) exposure
Number of subjects: 30
Study 35202552 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (Control)
Number of subjects: 30
Study 32610115 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K
Number of subjects: 339
Study 32533085 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 22
Study 32533085 — intervention group
Group type: COMPARATOR
Intervention: Sham (incomplete inflation of the blood-pressure cuff)
Number of subjects: 22
Study 35488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Visceral Manipulation (VM)
Number of subjects: 30
Study 35488711 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 30
Study 35488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + VM
Number of subjects: 30
Study 32956551 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Healing (SH)
Number of subjects: 0
Study 32956551 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM-CM (without immediate implant placement)
Number of subjects: 0
Study 32956551 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPL/DBBM-CM (with immediate implant placement)
Number of subjects: 0
Study 35840087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (3 mg, days 1, 8, 15)
Number of subjects: 57
Study 35840087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 34533091 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-range larvae
Number of subjects: 54
Study 34533091 — intervention group
Group type: COMPARATOR
Intervention: Larval-bag
Number of subjects: 54
Study 35447566 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON)
Number of subjects: 44
Study 35447566 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy (AR)
Number of subjects: 44
Study 34369940 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine exposure (25 mL rinsed four times a day during bleaching)
Number of subjects: 80
Study 34369940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no red wine)
Number of subjects: 80
Study 36374159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-containing BQT (bismuth potassium citrate 110 mg four times/day, esomeprazole 20 mg twice daily, metronidazole 400 mg four times/day, amoxicillin 500 mg four times/day)
Number of subjects: 404
Study 36374159 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline-containing BQT (tetracycline 500 mg four times/day, bismuth potassium citrate 110 mg four times/day, esomeprazole 20 mg twice daily, metronidazole 400 mg four times/day)
Number of subjects: 404
Study 34897105 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with gemcitabine
Number of subjects: 0
Study 34897105 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33565206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell (MSC) therapy with early tacrolimus withdrawal
Number of subjects: 57
Study 33565206 — intervention group
Group type: COMPARATOR
Intervention: Control tacrolimus group
Number of subjects: 57
Study 35670262 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) group
Number of subjects: 0
Study 35670262 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation group
Number of subjects: 0
Study 35670262 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep deprivation group
Number of subjects: 0
Study 35670262 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 33433720 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 20 mg/daily + cryotherapy
Number of subjects: 46
Study 33433720 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy only
Number of subjects: 46
Study 32385057 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of 4,137 proteins
Number of subjects: 5438
Study 32385057 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of observed protein associations
Number of subjects: 5438
Study 32385057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-directional two-sample Mendelian randomization analysis
Number of subjects: 5438
Study 36450541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 164
Study 36450541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 33263170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sucrosomial iron
Number of subjects: 0
Study 33263170 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium ferrigluconate
Number of subjects: 0
Study 34539392 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1600 mg*2 on the first day followed by 600 mg*2/day for 7 days)
Number of subjects: 240
Study 34539392 — intervention group
Group type: COMPARATOR
Intervention: Arbidol (200 mg*3/day for 7 days)
Number of subjects: 240
Study 35927622 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group exercise program with three counselling visits to physiotherapists over 9 months
Number of subjects: 119
Study 35927622 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 119
Study 34278887 — intervention group
Group type: EXPERIMENTAL
Intervention: Linzagolix (75-200 mg daily)
Number of subjects: 0
Study 34278887 — intervention group
Group type: EXPERIMENTAL
Intervention: Linzagolix (dose not specified)
Number of subjects: 0
Study 34601163 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multidrug injection (PMDI)
Number of subjects: 55
Study 34601163 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter (EC)
Number of subjects: 55
Study 35372959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, evidence-based intervention aimed at reducing HD-CRBSI
Number of subjects: 3615
Study 35372959 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 3615
Study 35165113 — intervention group
Group type: EXPERIMENTAL
Intervention: ProLife intervention (three brief motivational interviewing sessions and SMS messages)
Number of subjects: 574
Study 35165113 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 574
Study 35165113 — intervention group
Group type: EXPERIMENTAL
Intervention: ProLife intervention
Number of subjects: 574
Study 34325579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise group
Number of subjects: 32
Study 34325579 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily exercise including radio gymnastics and Jianxincao)
Number of subjects: 32
Study 35182846 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (ET)
Number of subjects: 39
Study 35182846 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheostomy (ST)
Number of subjects: 39
Study 34686129 — intervention group
Group type: EXPERIMENTAL
Intervention: Email delivery method
Number of subjects: 602
Study 34686129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid delivery method
Number of subjects: 602
Study 34686129 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mail delivery method
Number of subjects: 602
Study 32292074 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide daily
Number of subjects: 241
Study 32292074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 35676450 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ‐Z2301 (40 mg subcutaneously every other week for 24 weeks)
Number of subjects: 380
Study 35676450 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (subcutaneously every other week for 24 weeks)
Number of subjects: 380
Study 35676450 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ‐Z2301
Number of subjects: 380
Study 35676450 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 380
Study 35676450 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ‐Z2301 and adalimumab
Number of subjects: 380
Study 33500114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Processed Food (UPF) intake at 12 months
Number of subjects: 669
Study 33500114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Processed Food (UPF) intake at 24 months
Number of subjects: 669
Study 33500114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Processed Food (UPF) intake at 60 months
Number of subjects: 669
Study 33500114 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UPF intake between 24 and 60 months
Number of subjects: 669
Study 33500114 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors associated with UPF intake
Number of subjects: 669
Study 32067149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose droperidol (median dose 21 µg/kg)
Number of subjects: 34
Study 32067149 — intervention group
Group type: COMPARATOR
Intervention: Baseline motor‐evoked potential values
Number of subjects: 34
Study 33244559 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to spend time outdoors for 20-30 minutes daily for two months during summer
Number of subjects: 40
Study 33244559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 35065281 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 12-month intensive multimodal exercise intervention
Number of subjects: 0
Study 35065281 — intervention group
Group type: COMPARATOR
Intervention: Moderate aerobic exercise intervention
Number of subjects: 0
Study 33927212 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM)
Number of subjects: 20
Study 33927212 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 20
Study 33927212 — intervention group
Group type: EXPERIMENTAL
Intervention: I-GEL
Number of subjects: 20
Study 33927212 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 20
Study 33927212 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 20
Study 33040331 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient data analysis
Number of subjects: 526
Study 32184056 — intervention group
Group type: EXPERIMENTAL
Intervention: ED‐PN (Patient Navigation program)
Number of subjects: 100
Study 32184056 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 100
Study 33188692 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-catheter cryotherapy
Number of subjects: 100
Study 33188692 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 100
Study 616025870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Trabeculoplasty (PNT)
Number of subjects: 23
Study 34651606 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 5 mg, once daily for 42 days
Number of subjects: 36
Study 34651606 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 0.25 mg, once daily for 28 days
Number of subjects: 36
Study 34651606 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 0.75 mg, once daily for 28 days
Number of subjects: 36
Study 34651606 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (all doses)
Number of subjects: 36
Study 34651606 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir (0.25 mg)
Number of subjects: 36
Study 34651612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) at 95% of peak power output
Number of subjects: 10
Study 34651612 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT) at 50% of peak power output
Number of subjects: 10
Study 34651612 — intervention group
Group type: COMPARATOR
Intervention: Both HIIT and MICT
Number of subjects: 10
Study 35534823 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 6
Study 33167956 — intervention group
Group type: EXPERIMENTAL
Intervention: Area based stratified random sampling using GIS
Number of subjects: 217
Study 34861745 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block with saline peri-articular injection
Number of subjects: 62
Study 34861745 — intervention group
Group type: COMPARATOR
Intervention: Peri-articular injection with saline erector spinae plane block
Number of subjects: 62
Study 32063238 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reminiscence intervention program (10 weekly sessions lasting 2 hours each)
Number of subjects: 139
Study 32063238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 139
Study 32987943 — intervention group
Group type: EXPERIMENTAL
Intervention: Riceberry rice yogurt (350 g with 0.25% riceberry rice extract)
Number of subjects: 19
Study 32987943 — intervention group
Group type: EXPERIMENTAL
Intervention: Riceberry rice yogurt
Number of subjects: 19
Study 32987943 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 19
Study 35952766 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training program (IG)
Number of subjects: 123
Study 35952766 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 123
Study 33336530 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine swabstick
Number of subjects: 44
Study 33336530 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate
Number of subjects: 44
Study 32027918 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (n=2848)
Number of subjects: 7110
Study 32027918 — intervention group
Group type: COMPARATOR
Intervention: Diet-only intervention
Number of subjects: 7110
Study 32027918 — intervention group
Group type: COMPARATOR
Intervention: Physical activity-only intervention
Number of subjects: 7110
Study 32027918 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=2808)
Number of subjects: 7110
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (75.4% of interventions)
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (subgroup with absent FHR accelerations and absent-minimal FHR variability, n=332)
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (subgroup with FHR accelerations or moderate FHR variability, n=1,919)
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement to category I within 60 minutes
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement to category I within 60 minutes (n=1,433)
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: No improvement within 60 minutes (n=818)
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement to category I within 60 minutes
Number of subjects: 2251
Study 34352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of composite neonatal adverse outcome for category II tracings
Number of subjects: 2251
Study 32599496 — intervention group
Group type: EXPERIMENTAL
Intervention: NADA acupuncture
Number of subjects: 72
Study 32599496 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 72
Study 32599496 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 72
Study 32976088 — intervention group
Group type: EXPERIMENTAL
Intervention: DOM group performed a damaging eccentric exercise
Number of subjects: 10
Study 32976088 — intervention group
Group type: COMPARATOR
Intervention: CON group rested
Number of subjects: 10
Study 34014555 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX04
Number of subjects: 677
Study 34014555 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 677
Study 36228963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 1836
Study 36228963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1836
Study 32494976 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education plus stress management and relaxation training (DE + SMR)
Number of subjects: 50
Study 32494976 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education only (DE-only)
Number of subjects: 50
Study 35714315 — intervention group
Group type: EXPERIMENTAL
Intervention: One course of delayed intensification in low-risk group
Number of subjects: 3113
Study 35714315 — intervention group
Group type: EXPERIMENTAL
Intervention: Two delayed intensifications in low-risk group
Number of subjects: 3113
Study 35714315 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy in high-risk group
Number of subjects: 3113
Study 35714315 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy in high-risk group
Number of subjects: 3113
Study 35714315 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy in cytogenetic high-risk patients
Number of subjects: 3113
Study 35714315 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy in cytogenetic high-risk patients
Number of subjects: 3113
Study 32545655 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + HF group
Number of subjects: 220
Study 32545655 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + MF group
Number of subjects: 220
Study 32545655 — intervention group
Group type: EXPERIMENTAL
Intervention: T + HF group
Number of subjects: 220
Study 32545655 — intervention group
Group type: EXPERIMENTAL
Intervention: T + MF group
Number of subjects: 220
Study 35926882 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral (DL) approach with collared femoral stem
Number of subjects: 0
Study 35926882 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral (DL) approach with collarless femoral stem
Number of subjects: 0
Study 35926882 — intervention group
Group type: COMPARATOR
Intervention: Direct Anterior (DA) approach
Number of subjects: 0
Study 35926882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DL and DA)
Number of subjects: 0
Study 33341707 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose nab-paclitaxel (MD220) 220 mg/m2
Number of subjects: 141
Study 33341707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose nab-paclitaxel (LD180) 180 mg/m2
Number of subjects: 141
Study 33341707 — intervention group
Group type: COMPARATOR
Intervention: Standard dose nab-paclitaxel (SD260) 260 mg/m2
Number of subjects: 141
Study 32957959 — intervention group
Group type: COMPARATOR
Intervention: Standard education condition (information about benefits)
Number of subjects: 150
Study 32957959 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning (action planning, coping planning) + education condition
Number of subjects: 150